Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROOF personalized treatment study for pleural effusions in mesothelioma or lung cancer
NL-OMON40679Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2014
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in pleural mesothelioma and non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Accuracy of the drug profiling method. Planned start Jun 2014; status: not yet recruiting.
02
Conditions
pleural mesotheliomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON40679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40679.